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INTRODUCTION 
 
According to the American Cancer Society, an 
estimated 250,000 women will be diagnosed with breast 
cancer (BCa) this year alone and more than 40,000 
women will succumb to this devastating disease. Ductal 
carcinoma in situ (DCIS) is one of the earliest stages of 
BCa in which cancerous epithelial cells proliferate 
within the basement membrane of the breast milk duct. 
Importantly, DCIS lesions are associated with an 
increased risk of progressing to invasive breast cancer  
 
(IBC) over time [1–4]. Strikingly, 50% of DCIS 
recurrence presents as invasive cancer [5], thus 
understanding the molecular pathways involved in the 
development and progression of these pre-invasive 
lesions is key in bringing BCa to a halt at its early stage 
[1, 2, 5, 6]. 
 
Caveolin-1 (Cav-1) is an important 22-kDa integral 
membrane protein and structural component of caveolae 
implicated in the compartmentalization of signaling 
molecules [7, 8].  Cav-1 has been reported to positively 
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ABSTRACT 
 
Ductal carcinoma in situ (DCIS) is one of the earliest stages of breast cancer (BCa). The mechanisms by which 
DCIS lesions progress to an invasive state while others remain indolent are yet to be fully characterized and 
both diagnosis and treatment of this pre-invasive disease could benefit from better understanding the 
pathways involved. While a decreased expression of Caveolin-1 (Cav-1) in the tumor microenvironment of 
patients with DCIS breast cancer was linked to progression to invasive breast cancer (IBC), the downstream 
effector(s) contributing to this process remain elusive. The current report shows elevated expression of Signal 
Transducer and Activator of Transcription 5a (STAT5a) within the DCIS-like lesions in Cav-1 KO mice following 
estrogen treatment and inhibition of STAT5a expression prevented the formation of these mammary lesions. In 
addition, STAT5a overexpression in a human DCIS cell line (MCF10DCIS.com) promoted their invasion, a process 
accelerated by estrogen treatment and associated with increased levels of the matrix metalloproteinase-9 
(MMP-9) precursor. In sum, our results demonstrate a novel regulatory axis (Cav-1STAT5aMMP-9) in DCIS 
that is fully activated by the presence of estrogen. Our studies suggest to further study phosphorylated STAT5a 
(Y694) as a potential biomarker to guide and predict outcome of DCIS patient population. 
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and negatively impact tumor growth through tissue-
specific functions [9]. Although oncogenic properties of 
Cav-1 have been demonstrated in BCa, evidence 
suggests a tumor suppressive role of Cav-1 in BCa [7, 
10]. There is increasing attention to a specific role of 
Cav-1 in the tumor-associated stroma. A loss of Cav-1 
expression in the breast tumor stroma correlated with an 
increased risk for early recurrence, metastatic 
progression, and decreased survival in patients [11–13]. 
A retrospective patient cohort study revealed that nearly 
90% of estrogen receptor (ER) positive DCIS patients 
that had recurred to IBC showed diminished or 
completely absent Cav-1 expression in their tumor 
stroma [14]. Additional studies also demonstrated that 
loss of stromal Cav-1 expression coupled with the gain 
of stromal monocarboxylate transporter 4 (MCT4) 
expression was implicated in the transition of DCIS to 
IDC [15]. However, very little is currently known about 
the underlying mechanisms associated with DCIS 
formation and progression in the context of a Cav-1 
negative micro-environment.  
 
Signal transducer and activator of transcription 5a 
(STAT5a) is a transcription factor implicated in cell 
cycle progression, invasion, and migration in solid 
cancers [16, 17]. Hemizygous loss of STAT5a in a 
tumor-prone WAP-Simian Virus 40 T antigen (TAg) 
transgenic mouse model significantly delayed 
mammary cancer progression, as evidenced by a 
reduction in tumor size and number [18]. Conversely, 
transgenic overexpression of a constitutively activated 
STAT5a mutant or its upstream JAK2 activator was 
sufficient to cause tumor formation in the mammary 
glands of mice [19–21]. Most recently, a role of 
STAT5a signaling in pre-cancerous breast lesions was 
also reported, where hyperprolactinemia-inducing 
antipsychotics were demonstrated to induce activation 
of STAT5a and suppress apoptosis [22]. In addition, 
STAT5a-regulated NOX5-L expression increased the 
invasion and migration of human SK-BR-3 breast 
adenocarcinoma cells [23] and the inhibition of 
STAT5a by N-α-acetyltransferase protein (Naa10p) led 
to the suppression of cell motility and invasion in 
human MCF-7 and MDA-MB-231 BCa cells [24]. 
STAT5a was also shown to promote the progression of 
human atypical ductal hyperplasia (ADH), a precursor 
of DCIS [25].  
 
Surprisingly, there is very limited data on the 
contribution of STAT5a in the context of early BCa, 
especially DCIS formation and progression to invasive 
disease. However, knowing that several reports link 
STAT5a expression to tumor progression, and previous 
studies have demonstrated an inverted relationship of 
Cav-1 and STAT5a expression both in vitro and in vivo 
[26, 27], the current work focuses on the specific role 
(s) of STAT5a in early estrogen-stimulated BCa 
formation and progression, using both our established 
mouse model of estrogen-induced DCIS lesions in Cav-
1 KO mice [28] and in vitro human DCIS cells with 
differing STAT5a expression levels.  
 
Herein, our current report establishes that phosphorylated 
STAT5a (Y694) expression is significantly upregulated in 
the epithelia of DCIS lesions in Cav-1 KO mice following 
estrogen treatment, compared to wild-type (WT) mice. 
Functionally, STAT5a deletion in Cav-1 KO mice 
prevented mammary ductal branching and foci (DCIS-like 
lesion) formation, reduced the accumulation of PCNA 
positive epithelial cells, and maintained mammary ductal 
integrity by exhibiting both normal basement membrane 
and smooth muscle actin (myoepithelial) layer following 
estrogen treatment, suggesting that STAT5a could also 
play a role in invasion. Our results also demonstrate a 
direct contribution of STAT5a on the invasion of a human 
DCIS cell line (MCF10DCIS.com), an effect amplified by 
the presence of estrogen and associated with increased 
expression of a matrix metalloproteinase-9 (MMP-9) 
precursor protein levels. Collectively, we propose 
STAT5a as an important player into both DCIS formation 
and invasion and its phosphorylation on tyrosine 694 
(Y694) should be given closer attention as a potential 
target to prevent DCIS formation and transition to 
invasive cancer in a subset of high-risk patients such as 
those with a Cav-1 negative cancer stroma. Having a 
better understanding of STAT5a pathway in pre-invasive 
breast cancer could lead to the development of 
personalized therapies for high risk DCIS patients. 
 
RESULTS 
 
Cav-1 KO DCIS lesions display increased 
phosphorylated STAT5a (Y694) levels as a response 
to 17β-estradiol treatment 
 
As previously demonstrated, Cav-1 KO mammary 
glands show hypersensitivity to the proliferative effects 
of 17β-estradiol (E2) [28]. A similar protocol was 
utilized to examine if STAT5a was induced during this 
process and how its deletion could affect DCIS 
formation in these mice. Immunofluorescence data 
show that estrogen-treated Cav-1 KO mammary glands 
exhibit elevated levels of STAT5a (Y694), compared to 
WT counterparts (Figure 1A) and this increase was 
quantitatively analyzed as shown in Figure 1B (71.1-
fold, p<0.05, n=3 Cav-1 KO vs WT).  
 
Deletion of STAT5a in Cav-1 KO mice prevents 
mammary branching and DCIS-like foci formation 
 
Since DCIS-like lesions secondary to estrogen treatment 
in Cav-1 KO mice showed increased levels of 
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phosphorylated STAT5a (Y694) as shown in Figure 1, 
we questioned whether this was a bystander or 
functional effect of this transcription factor. To study 
this hypothesis, we compared branching and lesion 
formation in ovariectomized female WT, Cav-1 KO, and 
Cav-1/STAT5a double knockout (dKO) mice treated 
with an estrogen regimen for 60 days by performing 
whole mounts analysis. As shown in Figure 2A and 2B, 
estrogen-treated Cav-1 KO mice showed a significant 
increase in ductal branching (summation of primary, 
secondary, and tertiary branch points) compared to WT 
counterparts (2.9-fold, p<0.001, n=7-9). A homozygous 
deletion of STAT5a in Cav-1 KO mice was sufficient to 
significantly reduce the development of mammary 
branching compared to Cav-1 KO mice (1.5-fold, 
p<0.01, n=7-8), but still significantly higher than the WT 
group (1.9-fold, p<0.01, n=8-9) (Figure 2B: left panel). 
While mice lacking Cav-1 expression exhibited a 
significant increase in mammary foci formation 
following estrogen stimulation compared to WT mice 
(19.3-fold, p<0.01, n=7-9) (Figure 2B: right panel),  this 
increase was significantly reduced in Cav-1/STAT5a 
dKO mice (8.6-fold, p<0.01, n=7-8, compared to Cav-1 
KO mice) (Figure 2B: right panel) which reached the 
levels observed in WT mice (NS, p=0.164, n=8-9, WT 
vs Cav-1/STAT5a dKO). 
Proliferating cell nuclear antigen (PCNA) increase in 
Cav-1 KO DCIS-Like lesions secondary to estrogen 
treatment is inhibited by a homozygous STAT5a 
deletion 
 
The data above warranted further exploration into the role 
of STAT5a in estrogen-induced DCIS lesion formation 
grown within a Cav-1 negative mammary gland. PCNA, a 
cofactor of DNA polymerase that functions in the G1 and 
S phases of the cell cycle [29], was investigated through 
immunofluorescence in estrogen-stimulated WT, Cav-1 
KO, and Cav-1/STAT5a dKO mammary glands (Figure 
3). The increased level of PCNA nuclear expression 
observed in Cav-1 KO compared to WT mammary glands 
(middle panel) was reduced by a homozygous deletion of 
STAT5a in Cav-1 KO mice. These observations suggest 
an implication of STAT5a in the cell cycle progression of 
Cav-1 KO mammary lesions following estrogen 
treatment.  
 
Collagen and smooth muscle actin layer remain 
uninterrupted in Cav-1/STAT5a dKO mice 
mammary ducts following estrogen treatment 
 
Given the reported involvement of STAT5a in driving 
the progression of solid tumors [16–18, 23, 24], we
 
 
 
Figure 1. Cav-1 KO DCIS lesions display increased phosphorylated STAT5a (Y694) levels as a response to 17β-Estradiol 
treatment. (A) Mammary glands of estrogen-treated WT and Cav-1 KO mice were immunostained with an antibody recognizing 
phosphorylated STAT5a (Y694). DAPI was used as a nuclear counterstain. The EVOS FL microscope was used to capture images at 40x 
objective with the DAPI and CY5.5 light cubes (blue: DAPI immunostaining; green: phosphorylated STAT5a (Y694) immunostaining). For each 
experimental group, immunofluorescence was performed in triplicate on mammary glands derived from 3 independent mice. (B) 
Immunofluorescence staining was quantified using Image J software. Corrected total cell fluorescence (CTCF) was calculated using the 
following formula: CTCF = Integrated Density – (Area of Selected Region x Mean Fluorescence of Background). Cav-1 KO mammary glands 
demonstrated a significant increase in phosphorylated STAT5a (Y694) expression compared to estrogen-treated WT counterparts (71.1-fold, 
p<0.05, n=3). Data are expressed as % WT+E2.   
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Figure 2. Deletion of STAT5a in Cav-1 KO mice prevents mammary branching and DCIS-like foci formation. (A) Mammary glands 
of estrogen-treated WT, Cav-1 KO, and Cav-1/STAT5a dKO mice were subjected to whole mount analysis to assess ductal branching and foci 
formation. Images of the mammary gland whole mounts were captured at 40x objective using an Olympus DP71 camera. Black arrows 
indicate mammary foci. Original cohort sizes were as follows: WT+E2 (9 mice); Cav-1 KO+E2 (7 mice); Cav-1/STAT5a dKO+E2 (8 mice). (B) SAS 
programming software (version 9.4) was used to generate box plots displaying the number of ductal branching points (left panel) and the 
number of ductal foci (right panel) for each experimental group. Ductal branching was calculated as a summation of primary, secondary, and 
tertiary branch points. The absence of STAT5a in the Cav-1 KO mammary gland led to a decrease in both ductal branching and foci formation. 
Quantitatively, changes in ductal branching were as follows (left panel): WT vs. Cav-1 KO (2.9-fold, p<0.001), Cav-1 KO vs. Cav-1/STAT5a dKO 
(1.5-fold, p<0.01), WT vs. Cav-1/STAT5a dKO (1.9-fold, p<0.01). Quantitatively, changes in ductal foci were as follows (right panel): WT vs. 
Cav-1 KO (19.3-fold, p<0.01), Cav-1 KO vs. Cav-1/STAT5a dKO (8.6-fold, p<0.01), WT vs. Cav-1/STAT5a dKO (NS, p=0.164).  
 
 
 
Figure 3. Proliferating Cell Nuclear Antigen (PCNA) increase in Cav-1 KO DCIS-like lesions secondary to estrogen treatment is 
inhibited by a homozygous STAT5a deletion. Mammary glands of estrogen-treated WT, Cav-1 KO, and Cav-1/STAT5a dKO mice were 
immunostained with an antibody recognizing proliferating cell nuclear antigen (PCNA). DAPI was used as a nuclear counterstain. The EVOS FL 
microscope was used to capture images at 40x objective with the DAPI and Texas Red light cubes (blue: DAPI immunostaining; red: PCNA 
immunostaining). Qualitatively, mammary glands lacking Cav-1 expression showed elevated PCNA expression upon stimulation with estrogen 
compared to WT counterparts. A STAT5a deletion in the Cav-1 KO mammary gland diminished PCNA expression to WT levels. For each 
experimental group, immunofluorescence was performed in triplicate on mammary glands derived from 3 independent mice.   
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sought to examine closer whether a STAT5a deletion 
could restore mammary duct structural integrity in Cav-
1 KO mice treated with estrogen. While early DCIS 
lesions are well-contained within the basement 
membrane of the mammary ducts, later stages of DCIS 
are characterized by a dismantled basement membrane 
and the presence of micro-invasion, allowing cancer 
cells to invade outside into the stroma, a characteristic 
seen in Cav-1 KO mice treated with estrogen [1, 5, 28]. 
To assess how STAT5a deletion affected the 
histological morphology of the mammary ducts in Cav-
1 KO mice, we first stained WT, Cav-1 KO, and Cav-
1/STAT5a dKO mammary glands with Masson's 
Trichrome histochemical stain, which highlights 
collagen layers surrounding the outside of the mammary 
ducts (Figure 4A). Most intriguingly, collagen 
deposition (integrity of the basement membrane) was 
maintained in Cav-1 KO mammary glands lacking 
STAT5a expression (Figure 4A: right panel), similar to 
that observed in WT mice following estrogen treatment 
(Figure 4A: left panel). This is a significant change 
compared to the degradation of collagen seen around 
the DCIS lesions of estrogen-treated Cav-1 KO 
mammary glands (Figure 4A: middle panel). Closely 
associated with the inner side of the basement 
membrane is the smooth muscle layer that allows 
mammary ducts to contract during lactation 
(myoepithelial layer). This extra layer serves as a barrier 
that encloses the epithelial cells, preventing their 
invasion into the stroma [30]. To observe the integrity 
of the smooth muscle layer, we immunostained WT, 
Cav-1 KO, and Cav-1/STAT5a dKO mammary glands 
with an anti-alpha smooth muscle actin (SMA) antibody 
to visualize the distribution of myoepithelial cells lining 
the inside of the basement membrane of the mammary 
ducts (Figure 4B). Consistent with trichrome staining, 
Cav-1 KO mammary glands lacking STAT5a 
expression maintained a continuous smooth muscle 
layer (Figure 4B: bottom panels) similar to WT 
mammary ducts (Figure 4B: upper panels), compared to 
Cav-1 KO proliferative lesions which exhibited 
apparent breaks in the myoepithelial layers (Figure 4B: 
middle panels). These data suggest a possible role of 
STAT5a in promoting invasion of Cav-1 KO DCIS 
lesions.  
 
Western blot analysis following lentiviral-mediated 
overexpression of STAT5a in human 
MCF10DCIS.com  
 
To further explore the functional role of STAT5a in the 
progression of 17-β-estradiol-induced DCIS lesions 
seen in Cav-1 KO mice, we utilized a lentiviral 
transduction approach to overexpress STAT5a in human 
MCF10DCIS.com cells. The MCF10DCIS.com cell line 
is characterized by the presence of high grade, comedo 
DCIS-like structures and is an ideal model system for 
studying mechanisms involved in cancer progression 
[31]. Immunofluorescence staining showed successful 
nuclear overexpression of phosphorylated STAT5a 
(Y694) following lentiviral-mediated overexpression 
compared to empty control vector cells (Figure 5A). 
This was further confirmed by western blotting (Figure 
5B), where densitometry analysis demonstrated a 
significant increase in phosphorylated STAT5a (Y694) 
expression in STAT5a overexpressor cells in 
comparison to empty vector control cells (11.3-fold, 
p<0.01, n=3) (Figure 5C). Collectively, these data 
verify the successful overexpression of STAT5a in 
human MCF10DCIS.com cells. 
 
STAT5a overexpression in human DCIS cells drives 
invasion, a phenomenon enhanced by 17-β-estradiol 
treatment 
 
Qualitative images of invaded cells upon vehicle or 
estradiol treatment of empty vector vs. STAT5a 
overexpressor MCF10DCIS.com cells are depicted in 
Figure 6A. While both vehicle and estrogen-stimulated 
STAT5a overexpressor cells showed a significant 
increase in invasion compared to empty vector 
counterparts (1.9-fold, p<0.001. n=3, vehicle STAT5a 
overexpressor vs. empty vector) and (2.4-fold, p<0.001, 
n=3, estrogen STAT5a overexpressor vs. empty vector) 
(Figure 6B), invasion was significantly higher in the 
latter (estrogen treated group) (Figure 6B). In fact, the 
median change in invasion of estrogen-treated STAT5a 
overexpressor cells relative to estrogen-treated empty 
vector cells (median of 2.54, IQR of 0.39, n=3) was 
significantly greater compared to the median change in 
invasion of vehicle-treated STAT5a overexpressor cells 
relative to vehicle-treated empty vector cells (median of 
1.95, IQR of 0.49, n=3) (p<0.001, n=3) (Figure 6B). 
These data demonstrate that STAT5a overexpression 
accelerated the invasion of MCF10DCIS.com cells in an 
estrogen dependent manner. 
 
Increased Pro-MMP-9 protein expression secondary 
to STAT5a overexpression and 17-β-Estradiol 
treatment suggest a hormonal regulation of DCIS 
progression with this transcription factor 
 
To further investigate the mechanisms associated with 
invasiveness of MCF10DCIS.com STAT5a 
overexpressor cells in response to estrogen, we sought 
to examine the protein expression of downstream pro-
matrix metalloproteinase-9 (MMP-9). Pro-MMP-9 is a 
precursor that leads to the production of a basement 
membrane and extracellular matrix endopeptidase 
degrading enzyme to promote the invasion of cancer 
cells into the surrounding stroma, and is often used as 
an index of transcriptional regulation of this gene [32, 
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33]. Upon treating MCF10DCIS.com empty vector and 
STAT5a overexpressor cells with vehicle or estrogen, 
protein expression of pro-MMP-9 was determined by 
western blot (Figure 7A). Quantitatively, densitometry 
revealed that while pro-MMP-9 expression did not 
differ between vehicle-treated empty vector and 
vehicle-treated STAT5a overexpressor cells (NS, 
p=0.382, n=3) (Figure 7B), STAT5a overexpressor cells 
demonstrated a significant increase in protein 
expression of pro-MMP-9 compared to empty vector 
counterparts upon estrogen treatment (39.1-fold, 
p<0.001, n=3) (Figure 7B).  
DISCUSSION 
 
Currently, the molecular mechanisms that govern the 
transformation of non-invasive DCIS lesions to invasive 
carcinomas are not well understood [5]. Surgical 
excision, radiation, and endocrine therapy have become 
the standard treatment options to reduce the risk of 
disease progression, even for patients that would 
otherwise never evolve to IBC [34]. Traditionally, 
histological grade and hormone receptor status have 
been used to stratify DCIS patients according to their 
risk of recurrence and/or progression to IBC [35]. 
 
 
 
Figure 4. Collagen and smooth muscle actin layer remain uninterrupted in Cav-1/STAT5a dKO mice mammary ducts 
following estrogen treatment. (A) Mammary glands of estrogen-treated WT, Cav-1 KO, and Cav-1/STAT5a dKO mice were stained with 
Masson’s trichrome to highlight the collagen (blue staining) lining the outside of the basement membrane of the ducts. Qualitatively, Cav-1 
KO mammary glands stimulated with estrogen demonstrated a complete degradation of collagen surrounding the basement membrane, 
whereas WT ducts showed intact collagen deposition. Deletion of STAT5a from estrogen-treated Cav-1 KO mice restored collagen deposition 
to WT levels. For each experimental group, trichrome staining was performed in triplicate on mammary glands derived from 3 independent 
mice. (B) Mammary glands of estrogen-treated WT, Cav-1 KO, and Cav-1/STAT5a dKO mice were immunostained with an antibody 
recognizing alpha smooth muscle actin (SMA) to highlight the myoepithelial cells lining the inside of the basement membrane of the ducts. 
DAPI was used as a nuclear counterstain. The EVOS FL microscope was used to capture images at 40x objective with the DAPI and Texas Red 
light cubes (blue: DAPI immunostaining; red: SMA immunostaining). Qualitatively, the SMA layer surrounding estrogen-treated Cav-1 KO 
mammary ducts was disrupted (white arrows indicate breaks in the myoepithelial cells), but completely intact around WT ducts. Cav-1 KO 
mice lacking STAT5a expression maintained an intact SMA layer similar to WT mice. For each experimental group, immunofluorescence was 
performed in triplicate on mammary glands derived from 3 independent mice.   
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However, these features alone cannot reliably predict 
which DCIS lesions will progress to an invasive 
phenotype [1, 35]. As such, there is an unmet need to 
further understand the molecular pathways involved in 
DCIS progression. 
 
Studies have reported that an elevated expression of 
Cav-1 in the stroma of breast cancer patients confers 
significant protection against progression to metastases 
and associates with increased chances of survival [11] 
[36]. In contrast, Hart et al. have attributed a predictive 
value of Cav-1 expression in the epithelial compartment 
of invasive breast cancer [37]. Despite Cav-1 having a 
consistent prognostic value in breast cancer patients, the 
subtissular compartments associated with these effects 
seem to differ in the literature. Interestingly, studies 
focusing on protective effects of Cav-1 expression in 
the stroma reported its protein levels through stains with 
a Cav-1 antibody, while the Hart et al. study showing an 
epithelial protection of Cav-1 expression focused on 
mRNA levels, which might explain these contrasting 
observations. Our Cav-1 KO mouse model that develop 
accelerated DCIS-like lesion formation and invasion 
secondary to estrogen treatment as previously 
published, seems to be an appropriate model [28] to 
uncover the potential mechanisms involved in 
accelerated DCIS invasion in patients with a lack of 
stromal Cav-1.  
 
Our current data implicates a functional role of STAT5a 
in the epithelial compartment of DCIS. Lowering 
STAT5a levels in estrogen-induced Cav-1 knockout 
DCIS model in mice prevented lesions formation, 
restored collagen deposition, maintained myoepithelial 
cell layer, and decreased PCNA-positive epithelial cells. 
Although these results are very exciting and might 
 
 
 
Figure 5. Western blot analysis following lentiviral-mediated overexpression of STAT5a in human MCF10DCIS.com. (A) 
Immunofluorescence staining was used to confirm overexpression of phosphorylated STAT5a (Y694) in MCF10DCIS.com cells. Empty vector 
and STAT5a overexpressor cells were immunostained with an antibody recognizing phosphorylated STAT5a (Y694). DAPI was used as a 
nuclear counterstain. The EVOS FL microscope was used to capture images at 40x objective with the DAPI and Texas Red light cubes (blue: 
DAPI immunostaining; red: phosphorylated STAT5a (Y694) immunostaining). Qualitatively, phosphorylated STAT5a (Y694) expression was 
upregulated in STAT5a overexpressor cells compared to empty vector control cells. Immunofluorescence was performed in triplicate on cells 
derived from 3 independent passages. (B) Western blotting was used to confirm overexpression of phosphorylated STAT5a (Y694) in 
MCF10DCIS.com cells. Whole cell lysates (100μg) of empty vector and STAT5a overexpressor cells were used to assess the protein expression 
of phosphorylated STAT5a (Y694) and total STAT5a. GAPDH was used as a control for equal loading. Western blotting was performed in 
triplicate on cells derived from 3 independent passages. (C) Densitometry analysis was performed using the LI-COR imager. A ratio of 
phosphorylated STAT5a (Y694) to total STAT5a was calculated upon normalizing to respective loading controls. Data are reported as % empty 
vector. Quantitatively, phosphorylated STAT5a (Y694) expression was upregulated in MCF10DCIS.com STAT5a overexpressor cells compared 
to empty vector control cells (11.3-fold, p<0.01, n=3). 
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highlight a previously unidentified role of STAT5a in 
estrogen-induced DCIS formation, our in vivo model 
has certain limitations that should be noted. Firstly, all 
compartments of the mammary gland of the Cav-1 
knockout mice growing these DCIS lesions lack Cav-1 
expression (including both stromal and epithelial where 
the DCIS arise). Future studies will be developed to 
focus more specifically on the role of STAT5a as it 
relates to a lack of Cav-1 in the stroma, to closely 
reproduce the studies in patients [14, 15]. This might be 
performed by using human CAFs with and without Cav-
1 expression that will be co-injected with human DCIS 
cells to look at STA5a signaling. Another limitation of 
our current in vivo model is that STAT5a was deleted in 
the mammary glands of Cav-1 KO mice from birth 
which might also modify how this hormonally regulated 
tissue might develop and further respond to estrogen to 
form DCIS lesions. For this specific reason, we set out 
to examine the role of STAT5a in an in vitro model 
system of already established DCIS using the human 
MCF10DCIS.com cell line, to better understand the 
direct contribution of this transcription factor in DCIS 
progression. MCF10DCIS.com cell line originates from 
DCIS lesions with comedo growth patterns created by 
the injection of T24 c-Ha-ras oncogene-transformed 
MCF10A (MCF10AT) cells into severe combined 
immune-deficient (SCID) mice. This cell line is an ideal 
in vitro model for studying human DCIS progression 
[38]. Our current report also demonstrates that STAT5a 
overexpression in a human DCIS cell causes increased 
invasion when treated with estradiol. Together our 
results indicate a possible implication of STAT5a in 
estrogen-stimulated DCIS progression, a phenomenon 
that could be initiated by a decrease in stromal Cav-1 in 
vivo, and this possibility will also be tested in future 
studies with co-cultures with cancer fibroblasts.  
 
 
 
Figure 6. STAT5a overexpression in human DCIS cells drives invasion, a phenomenon enhanced by 17-β-Estradiol treatment. 
(A) Qualitatively, transwell invasion assay results depict DAPI-stained invaded cells after 18- hour treatment of MCF10DCIS.com empty vector 
or STAT5a overexpressor cells with vehicle (DMSO) or 1nM estradiol. Images of the invaded cells were captured using the DAPI channel on 
the EVOS FL microscope at 10x objective. (B) Quantitatively, the number of invaded cells in five representative fields of view were averaged 
for each membrane. Data were normalized to empty vector. Treatment with vehicle or 1nM estradiol led to a significant increase in invasion 
of STAT5a overexpressor cells compared to empty vector cells (vehicle-treated empty vector vs. STAT5a overexpressor cells: 1.9-fold, 
p<0.001, n=3; estrogen-treated empty vector vs. STAT5a overexpressor cells: 2.4-fold, p<0.001, n=3). Moreover, the invasion of STAT5a 
overexpressor cells relative to empty vector cells was calculated independently for each treatment group and reported as a median change in 
invasion with an associated interquartile range (IQR) (vehicle [STAT5a overexpressor/empty vector]: 1.95 median, 0.49 IQR, p<0.001, n=3; 
estrogen [STAT5a overexpressor/empty vector]: 2.54 median, 0.39 IQR, p<0.001, n=3). The median change in invasion of estrogen-treated 
STAT5a overexpressor cells relative to empty vector cells was significantly higher compared to the median change in invasion of vehicle-
treated STAT5a overexpressor cells relative to empty vector cells (p<0.001, n=3). 
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To our knowledge, no previous studies have yet 
implicated STAT5a as an important transcription factor 
actively involved in DCIS formation and invasion. 
While several studies ascribe a pro-tumorigenic 
function of STAT5a in many cancers as described 
above [16–21], its role in human BCa remains 
somewhat mixed and controversial. For example,  
STAT5a expression was predictive of increased overall 
survival and response to endocrine therapy in ER-
positive human invasive breast cancer [39]. In addition, 
in vitro experiments demonstrated that STAT5a 
inhibited the invasion of well-differentiated ER positive 
human T-47D cells and poorly differentiated ER 
negative human BT-20 cells [40]. Taken together, these 
published reports indicate so far, a dual functionality of 
STAT5a in human BCa, which seems dependent upon 
cellular context and the stage of BCa, only to name a 
few. Although our study demonstrates STAT5a as a key 
factor during DCIS formation in vivo and which also 
stimulates pro-invasive properties in a DCIS model in 
vitro, more studies will be warranted to fully understand 
its biological role in early cancer progression. An 
important result shown in our current report here 
suggests that estrogen treatment enhances the pro-
tumorigenic properties of STAT5a in our DCIS models. 
So far, very little attention has been given to a potential 
synergism between STAT5a and estrogen signaling, 
especially in the context of DCIS formation and 
progression, and which might also explain differing 
roles of STAT5a in breast cancer. Furthermore, it 
appears that paying closer attention to the subtype of 
estrogen receptor(s) expressed by the cells when 
STAT5a is present might also be of importance in fully 
predicting breast cancer cell behaviors. Despite lacking 
the expression of a traditional nuclear estrogen receptor 
alpha (ER-α) [41], MCF10DCIS.com invaded 
significantly more following estrogen treatment when 
STAT5a was overexpressed. This could be explained by 
an alternatively spliced variant of full-length ER-α, a 
shorter ER isoform (ER-α36) and a key mediator of 
non-genomic estrogen signaling pathways [42, 43] also 
shown to mediate Scr/EGFR/STAT5 pathway activation 
 
 
 
Figure 7. Pro-MMP-9 protein expression secondary to STAT5a overexpression and 17-β-Estradiol treatment suggest a 
hormonal regulation of DCIS progression with this transcription factor. (A) MCF10DCIS.com empty vector and STAT5a 
overexpressor cells were treated with vehicle (DMSO) or 1nM estradiol for 24 hours. Whole cell lysates (75μg) were used to assess the 
protein expression of MMP-9. GAPDH was used as a loading control. Western blotting was performed in triplicate on cells derived from 3 
independent passages. (B) Using the LI-COR imager, densitometry was used to determine the protein expression of MMP-9 upon 
normalizing to the loading control. Data are reported as % empty vector. Quantitatively, no significant difference in MMP-9 expression was 
observed between vehicle-treated empty vector and STAT5a overexpressor cells (NS, p=0.382, n=3). Upon treatment with estrogen, a 
significant increase in MMP-9 protein expression was observed in STAT5a overexpressor cells compared to empty vector cells (39.1-fold, 
p<0.001, n=3). 
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and mitogenic effects in ER-negative TNBC cell lines 
[44, 45]. It could be speculated that the contribution of 
STAT5a on invasion following estrogen treatment could 
result from a crosstalk between membrane localized ER-
α36 and neighboring growth factor receptors. Important 
future experiments will focus on overexpressing a 
traditional nuclear ER-alpha (66KDa) in 
MCF10DCIS.com and assess whether STAT5a will 
maintain its pro-invasive properties and/or knocking down 
ER-alpha 36. Interestingly, a previous study showed that 
in a model of traditional nuclear ER-alpha-66 
overexpression, a deletion of STAT5a did not prevent 
chemically-induced tumors in the presence of estrogen, 
which could also hint at the importance of the ER 
subtypes to fully understand the role of this transcription 
factor [46]. Also important to mention, is that our current 
models did not focus on any potential roles or 
contributions of STAT3, a different related isoform. 
STAT3 was discovered to have non redundant and 
sometimes even opposing effects as STAT5a. For 
example, in T-47D and SK-BR-3 breast cancer cell lines, 
STAT5a and STAT3 differentially regulated BCL-6 
expression, a protein involved in apoptosis [47]. In 
addition, STAT5a seems to have a dominant effect over 
STAT3 when co-expressed in the same cell, also a very 
interesting observation [47]. Although our models herein 
did not co-express STAT3 and STAT5a or specifically 
looked at the functional role of STAT3, our future studies 
will focus on the effects of these 2 transcription factors 
alone and together in DCIS cell model systems. In sum, 
clarification of these potential mechanisms of action will 
be warranted in future pathway exploration studies in 
human DCIS models.  
 
To further our mechanistic knowledge of the pro-
invasive role of STAT5a, we assessed the levels of pro-
MMP-9, a pro-enzyme that facilitates degradation and 
proteolysis of the extracellular matrix to promote cancer 
cell dissemination and metastasis [32]. Intriguingly, we 
observed a dramatic upregulation of pro-MMP-9 protein 
expression in MCF10DCIS.com cells overexpressing 
STAT5a stimulated with estrogen treatment. The 
recruitment of this enzyme by STAT5a in DCIS would 
be consistent with previous studies demonstrating that 
siRNA and overexpression of MMP-9 modulate 
invasion, motility and alterations of cytoskeletal 
components [48]. Our results are also consistent with 
previous reports confirming a transcriptional regulation 
of MMP-9 by STAT5a [49]. STAT5a was also 
previously shown to cause changes associated with 
epithelial to mesenchymal transition, also consistent 
with our observation of increased invasion in DCIS 
cells by this transcription factor [50]. A possible 
connection between a lack of stromal Cav-1 and an 
increase in STAT5a in the epithelial DCIS lesion could 
be through cytokine secretion, through interleukin-6 
(IL-6). Interestingly, Cav-1 null mouse fibroblasts have 
been previously demonstrated to secrete significantly 
more IL-6 when compared to their wild-type 
counterparts [51]. Interleukin-6 is a very important 
cancer cytokine and it is known to be capable of 
activating the STAT pathway [52]. Whether preventing 
upstream interleukin-6 secretion by cancer-associated 
fibroblasts (CAFs) could halt the progression of DCIS 
lesions to invasive cancer in high-risk DCIS breast 
cancer patients, such as those with low stromal Cav-1 
expression, remains to be elucidated and could have 
significant clinical impact.  
 
To our knowledge, no studies have yet correlated the 
levels of STAT5a, especially the Y694 phosphorylated 
form, to histological grades of DCIS and invasive 
potential in vivo or in patients. Although Shan et al. 
have previously detected STAT5a in DCIS lesions of 
chemically-induced rat lesions and human samples, they 
have not correlated its expression or phosphorylation 
with histological grade of DCIS [53], therefore this 
would be a clinically important study to perform and 
follow up on in a near future. Our future experiments 
also plan to further our knowledge on the paracrine 
influence of the stromal cancer compartment on 
epithelial STAT5a signaling by performing co-culture 
experiments of CAFs both in vitro and in vivo also as 
mentioned above. Our results here thus suggest that 
there is a potential complex signaling event occurring 
that could begin in the microenvironment of pre-
cancerous patients that could signal and push DCIS 
lesions to begin invading in some patients and our 
results point towards a novel regulatory axis (Cav-
1STAT5aMMP-9) that might enable a better 
understanding of the early events involved in the 
progression of DCIS lesions to invasive cancers.  
 
In summary, whether phosphorylated STAT5a (Y694) 
could serve as a clinical biomarker and potential target 
to help treat Cav-1-depleted DCIS population at greater 
risk of progressing to IBC remains a future avenue for 
further exploration. While the presented study is 
preliminary in nature, we are hopeful that current results 
will contribute to a better understanding of DCIS 
progression and potential new avenue of treatment for 
high risk DCIS patient populations and open up many 
future research endeavors that will focus on this 
pathway, especially in the context of estrogen 
stimulation.  
 
MATERIALS AND METHODS 
 
Antibodies 
 
An anti-rabbit monoclonal antibody (mAb) against 
phosphorylated STAT5a (Y694) (Cat#9314S) was 
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purchased from Cell Signaling Technology (Danvers, 
MA). An anti-mouse mAb against alpha smooth muscle 
actin (Cat#ab7817) were purchased from Abcam 
(Cambridge, MA). Anti-mouse mAbs against PCNA 
(Cat#sc-56) and MMP-9 (Cat#sc-393859) were 
purchased from Santa Cruz Biotechnology (Santa Cruz, 
CA). An anti-mouse mAb against glyceradehyde-3-
phosphate dehydrogenase (GAPDH) (Cat#10R-2932) 
was purchased from Fitzgerald Industries International 
(Acton, MA).  
 
Mouse model 
 
This study was conducted according to the guidelines of 
the National Institutes of Health (NIH) and the Thomas 
Jefferson University Institute for Animal Studies. 
Approval was granted by the Institutional Animal Care 
and Use Committee (IACUC) at Thomas Jefferson 
University. All mice used in this study were in the 
FVB/N genetic background. Experimental groups 
included wild type (WT), Cav-1 knockout (KO), and 
Cav-1/STAT5a double knockout (dKO) mice. WT mice 
and STAT5a mice were purchased from Jackson 
Laboratories (Bar Harbor, Maine). Cav-1 KO mice were 
generated as previously described [54]. To generate the 
Cav-1/STAT5a dKO mice, Cav-1 KO female mice were 
bred with STAT5a male mice to generate Cav-
1/STAT5a heterozygotes. Then, female and male 
heterozygotes (Cav-1/STAT5a) were bred to generate 
Cav-1/STAT5a dKO mice. To maintain the colony, 
male Cav-1/STAT5a dKO mice were bred with female 
Cav-1 KO/STAT5a heterozygotes since the complete 
lack of STAT5a interferes with proper lactation [55]. 
Genotypes were confirmed by polymerase chain 
reaction (PCR) as followed by Jackson Laboratories 
protocol (Bar Harbor, Maine). 
 
Bilateral ovariectomy procedure 
 
Mice were ovariectomized as previously described [28]. 
Briefly, 5-week old female WT, Cav-1 KO, and Cav-
1/STAT5a dKO mice were anesthetized using 5mg/kg 
xylazine and 50mg/kg ketamine. A single dorsal 
incision followed by ligation of the ovarian arteries and 
veins with a 4-0 silk suture was performed, followed by 
the excision of both ovaries. The incision site was 
subsequently closed with a 5-0 silk suture and the mice 
were administered a subcutaneous injection of analgesic 
(0.1mg/kg buprenorphine). Mice were allowed to 
recuperate for 2 weeks before being randomly assigned 
to 2 replacement pellets containing 17-β-estradiol (7.5 
mg/pellet; 60-day slow release; 125 μg/day) or placebo 
pellets (Innovative Research of America, Sarasota, FL). 
Implantation of slow-release pellets was performed 
under anesthesia by lifting the skin on the lateral side of 
the neck of the mice and by making an incision equal in 
diameter to that of the pellet. Then, with a pair of 
forceps, a horizontal pocket of about 2 cm beyond the 
incision site was created, and the pellet was introduced. 
The incision site was closed with a 5-0 silk suture.  
 
Preparation of tissues 
 
Mice were euthanized by inhalation of CO2 
(compressed CO2 gas cylinder) at 60 days following 
pellet implantation. After the mice were euthanized, the 
inguinal mammary gland #4 was excised and fixed in 
formalin for 24 hours, paraffin-embedded, and cut into 
5 µm sections for histological analyses.  
 
Immunofluorescence on tissues 
 
Paraffin-embedded sections of mammary glands were 
dehydrated in xylene for 20 minutes and rehydrated in a 
series of graded ethanol solutions and distilled water for 
5 minutes each. Tissues were then incubated in a citric 
acid-based antigen unmasking solution with an acidic 
pH (Cat#H-3300, Vector Laboratories, Burlingame, 
CA) using an electric pressure cooker on high pressure 
for 5 minutes. Tissues were washed three times with 
Dulbecco’s phosphate buffered saline (DPBS) (1x) for 5 
minutes each wash. Then, tissues were blocked with 
10% goat normal serum (Cat#S-1000, Vector 
Laboratories, Burlingame, CA) for 1 hour at room 
temperature and incubated with a given primary 
antibody (1:50 dilution) overnight at 4°C. The following 
day, tissues were washed with DPBS (1x) three times 
for 5 minutes each wash and then incubated with Alexa 
Fluor 594 or 647-conjugated secondary antibodies 
(1:250 dilution) for 30 minutes at room temperature 
(ThermoFisher Scientific, Waltham, MA). Lastly, 
tissues were washed with DPBS (1x) before being 
mounted with ProLong Gold Antifade with 4’6-
diamidino-2-phenylindole (DAPI) (Cat#P36931, 
ThermoFisher Scientific, Waltham, MA). Nail polish 
was applied around the perimeter of the coverslips to 
prevent the tissues from drying out. Images were 
acquired on the EVOS FL microscope using the DAPI, 
Texas Red, or CY5.5 light cubes at 40x objective 
(ThermoFisher Scientific, Waltham, MA).  
 
Mammary gland whole mounts 
 
Mammary glands were fixed in Carnoy’s fixative (six 
parts 100% ethanol: three parts chloroform: one part 
glacial acetic acid) for 2 to 4 hours at room temperature. 
Mammary glands were then washed in 70% ethanol for 
20 minutes and changed to decreasing amounts of 
ethanol and finally to distilled water. The mammary 
glands were stained overnight in a solution of 0.2% 
carmine and 0.5% aluminum potassium phosphate 
(Sigma-Aldrich, St. Louis, MO). Mammary glands were 
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then dehydrated using graded ethanol solutions and left 
in xylene to clear the fat. Mammary gland whole 
mounts were stored in methyl-salicylate. Images were 
captured at 40x using an Olympus DP71 camera.  
 
Trichrome staining 
 
Masson’s trichrome method for connective tissue 
(Cat#k037) was adopted from Poly Scientific R&D 
Corporation (Bayshore, NY). Briefly, tissues were 
placed in Bouin’s Fixative overnight at room 
temperature to increase the intensity of the stain. 
Tissues were washed in running tap water for 10 
minutes followed by a distilled water rinse prior to 
being submerged in Weigert’s Iron Hematoxylin 
Working Solution for 10 minutes. Tissues were then 
washed in running tap water for 10 minutes followed by 
a distilled water rinse prior to being placed in Biebrich 
Scarlet Acid Fuchsin. Tissues were rinsed twice with 
distilled water for 15 seconds and subsequently placed 
in Phosphotungstic Phosphomolybdic Acid for 12 
minutes. Tissues were then submerged in Aniline Blue 
Solution for 20 minutes followed by two 15 second 
distilled water rinses. Lastly, tissues were placed in 1% 
Acetic Acid to clear the tissues of any loosely bound 
dye. Tissues were dehydrated in a series of ethanol 
solutions, placed in xylene for 5 minutes, and mounted 
with Permount (ThermoFisher Scientific, Waltham, 
MA). Images were acquired at 40x using the EVOS XL 
Core microscope. 
 
Cell lines 
 
MCF10DCIS.com cells were obtained through a 
Material Transfer Agreement with the Barbara Ann 
Karmanos Cancer Institute at Wayne State University. 
The MCF10DCIS.com cell line was cultured in phenol-
free DMEM/F12 medium (Cat#21041025, 
ThermoFisher Scientific, Waltham, MA) supplemented 
with 5.26% charcoal-stripped horse serum 
(Cat#NC9058780, ThermoFisher Scientific, Waltham, 
MA), 1.05mM calcium chloride (Cat#21115-100ML, 
Sigma-Aldrich, St. Louis, MO), and 10mM HEPES 
(Cat#15630080, ThermoFisher Scientific, Waltham, 
MA). 293T cells (Cat#CRL-3216, ATCC, Manassas, 
VA) were cultured in DMEM medium (Cat#11965118) 
supplemented with 10% fetal bovine serum (FBS) 
(Cat#16140071) and 1% penicillin/streptomycin 
(Cat#15140163) (ThermoFisher Scientific, Waltham, 
MA). All cell lines were incubated at 37°C / 5% CO2. 
 
Bacterial transformation and lentiviral transduction 
 
All work involving bacterial transformation and 
lentiviral transduction was approved by the Institutional 
BioSafety Committee at University of the Sciences. A 
STAT5a plasmid (TRCN0000473086, NM_003152.3) 
and an Empty Vector plasmid (ORFPUR) were 
purchased from Sigma-Aldrich (St. Louis, MO). 
Briefly, plasmids were grown up to desired 
concentrations using GCIL3 ultracompetent bacteria by 
selecting with ampicillin (50mg/mL). Plasmid DNA 
was isolated, purified, and precipitated using the 
PureLink HiPure Plasmid Filter Maxiprep Kit 
(Cat#K210016, ThermoFisher Scientific, Waltham, 
MA). Next, 293T packaging cells were co-transfected 
with the plasmids and the Lenti-Pac HIV Expression 
Packaging Kit (Cat#LT001, GeneCopoeia, Rockville, 
MD) to produce lentiviral particles. Lastly, 
MCF10DCIS.com cells were infected with 1mL of 
Empty Vector or STAT5a Overexpressor lentiviral 
particles in complete medium supplemented with 
5μg/mL Polybrene for 24 hours (Cat#sc-134220, Santa 
Cruz Biotechnology, Santa Cruz, CA). Stable cell lines 
were generated upon selection with 10μg/mL 
puromycin dihydrochloride for two weeks (Cat#108071, 
Santa Cruz Biotechnology, Santa Cruz, CA). 
 
Immunofluorescence on cells 
 
Briefly, 2.0 x 105 cells were seeded on poly-l-lysine 
coated coverslips (Cat#P4707, Sigma-Aldrich, St. 
Louis, MO) in 6 well plates (Cat#3516, Corning, 
Corning, NY). The following day, cells were fixed in 
4% paraformaldehyde (Cat#159-SP, Electron 
Microscopy Sciences, Hatfield, PA) for 15 minutes at 
room temperature. Fixed cells were washed three times 
with DPBS (1x) and then permeabilized in 100% 
methanol for 10 minutes at -20°C. Following another 
DPBS (1x) wash, cells were blocked in blocking buffer 
(DPBS 1x, 5% normal serum, 0.3% Triton X-100) for 
60 minutes at room temperature. Cells were then 
incubated with a given primary antibody (1:50 dilution 
in DPBS 1x, 1% BSA, 0.3% Triton X-100) for 1 hour at 
37°C. After three DPBS (1x) washes, cells were 
incubated with an Alexa Fluor 594-conjugated goat 
anti-rabbit secondary antibody (1:500 dilution in DPBS 
1x, 1% BSA, 0.3% Triton X-100) for 1 hour at 37°C 
(Cat#A-11012, ThermoFisher Scientific, Waltham, 
MA). Cells were washed three times with DPBS (1x) 
before being mounted with ProLong Gold Antifade with 
DAPI (Cat#P36931, ThermoFisher Scientific, Waltham, 
MA). Using the EVOS FL microscope, images were 
acquired at 40x objective using the DAPI and Texas 
Red light cubes. 
 
Transwell invasion assay 
 
Briefly, 1.5 x 105 cells were resuspended in 500uL of 
phenol-free growth medium containing a reduced serum 
concentration of 0.5% charcoal-stripped horse serum. 
Culture medium was supplemented with vehicle 
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(DMSO) or 1nM estradiol (Cat#E1024-1G, Sigma-
Aldrich, St. Louis, MO). Cells were then seeded in 
invasion chambers with membranes (8μm pore size) 
pre-coated with growth factor reduced matrigel 
(Cat#354483, Corning, Corning, NY). Invasion 
chambers were placed in 24 well plates (Cat#353047, 
Corning, Corning, NY), with each well containing 
750uL of phenol-free growth medium at a normal serum 
concentration of 5.26% charcoal stripped horse serum. 
Chambers were incubated at 37°C/5% CO2 for 18 hours 
to allow cells to invade. The following day, the inner 
membranes of the chambers were washed with PBS 
(1x) and gently scraped with cotton swabs to remove 
any non-invaded cells and the matrigel layer. Invaded 
cells located on the outer membrane were fixed with 
100% methanol at room temperature for 10 minutes, 
rinsed with distilled water, and left to dry before being 
mounted with Vectashield mounting medium with 
DAPI (Cat#H-1200, Vector Laboratories, Burlingame, 
CA). Using the EVOS FL microscope, five 
representative fields of view of the DAPI-stained 
invaded cells on each membrane at captured at 10x 
objective (ThermoFisher Scientific, Waltham, MA).  
 
Western blot 
 
Samples were homogenized in RIPA lysis buffer 
(50mM Tris pH 7.5, 150 mM NaCl, 1% Nonidet P-40, 
0.5% deoxycholate, 0.1% SDS) supplemented with 
complete mini protease inhibitor cocktail 
(Cat#NC0969110, Roche Diagnostics, Basel, 
Switzerland) and phosphatase inhibitor cocktail 
(Cat#78428, ThermoFisher Scientific, Waltham, MA). 
After homogenization, samples were sonicated and 
centrifuged at 10,000 x rpm for 10 minutes at 4°C. 
Supernatant was then collected for measurement of 
protein concentration using a bicinchoninic acid (BCA) 
kit (Cat#23225, ThermoFisher Scientific, Waltham, 
MA). Samples (75μg -100μg) were separated by SDS-
PAGE (12% acrylamide) and transferred to a 
nitrocellulose membrane (Cat#45-004-001, GE 
Healthcare, Chicage, IL) for probing. Subsequent wash 
buffers consisted of 10 mM Tris pH 8.0, 150 mM NaCl, 
0.05% Tween 20 (TBS-T). Membranes were blocked in 
TBS-T supplemented with 5% bovine serum albumin 
(BSA) (Cat#BP1600-100, ThermoFisher Scientific, 
Waltham, MA) or 5% nonfat dry milk (Cat#50-447-
778, Quality Biological Inc., Gaithersburg, MD) for 1 
hour at room temperature. The membranes were 
subsequently incubated with a given primary antibody 
(1:100 to 1:500 dilution) overnight at 4°C. IRDye 
680RD or 800CW secondary antibodies (1:15,000 
dilution) were used to visualize bound primary 
antibodies (LI-COR, Lincoln, NE). The Odyssey CLx 
Imaging System was utilized for near-infrared (NIR) 
fluorescent detection of proteins (LI-COR, Lincoln, 
NE). Image Studio software version 5 on the Odyssey 
CLx was used to quantify Western bands (LI-COR, 
Lincoln, NE).   
 
Statistical analysis 
 
Statistical analyses were performed using Excel and 
SAS software version 9.4 (SAS Institute Inc., Cary, 
NC). Differences in ductal branching were evaluated 
using a one-way ANOVA followed by posthoc 
Bonferroni adjusted tests for multiple comparison. 
Differences in ductal foci formation were evaluated 
using a Kruskal-Wallis test followed by posthoc 
adjusted tests for multiple comparisons based on the 
Dwass, Steel, Critchlow-Fligner method. Comparisons 
involving only two groups were analyzed using a two-
tailed t-test. Data were reported as mean +/- standard 
error of the mean (SEM). Differences in fold change 
between groups were analyzed using a Wilcoxon two-
sample test. Median and interquartile range (IQR) were 
reported. Statistical significance was reached at p<0.05 
(*)(#)(†), p<0.01 (**)(##)(††), and p<0.001 
(***)(###)(†††).  
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